Rapid eye movement sleep behavior disorder: A proof-of-concept neuroprotection study for prodromal synucleinopathies.
Dario ArnaldiFrancesco FamàNicola GirtlerAndrea BrugnoloMatteo PardiniPietro MattioliRiccardo MeliFederico MassaBeatrice OrsoMaria Pia SormaniMaria Isabella DoneganiMatteo BaucknehtSilvia MorbelliFlavio NobiliPublished in: European journal of neurology (2020)
A 30-months neuroprotection study for prodromal synucleinopathy is feasible, using iRBD as the target population and 123 I-FP-CIT-SPECT as a biomarker of disease progression.